Drug Trial Radar · NCT04977986
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
257
Actual
Start
Sep 13, 2021
Primary completion
Aug 29, 2025
Study completion Aug 29, 2025
Sponsor
- Lead sponsor
- Harmony Biosciences Management, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 29 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to \< 30 years will be eligible to participate.
Conditions
- Fragile X Syndrome
- Fragile X Syndrome (FXS)
Interventions
ZYN002Drug
Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
PlaceboDrug
Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery) Other Names: Placebo Comparator Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1 score in patients with complete methylation of the FMR1 gene.Time frame: Change from Baseline to Week 18
Locations
27 sites in 5 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Science 37
Culver City, California
Amnova Clinical Research, LLC
Irvine, California
Thompson Autism Center CHOC
Orange, California
UC Davis Health System, MIND Institute
Sacramento, California
Children's National Medical center
Washington D.C., District of Columbia
University of Miami
Miami, Florida
Rare Disease Research
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Kennedy Krieger Institute
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
University of Minnesota Fragile X Clinic (Voyager Clinic)
Minneapolis, Minnesota
University of Mississippi
Jackson, Mississippi
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics
New York, New York
Central States Research
Tulsa, Oklahoma
Penn State Hershey Medical Center
Hershey, Pennsylvania
Greenwood Genetic Center
Greenville, South Carolina
Primary Children's Hospital
Salt Lake City, Utah
Westmead Children's Hospital
Sydney, New South Wales, Australia
Lady Cilento Children's Hospital - South Brisbane
Brisbane, Queensland, Australia
Genetics Clinics Australia
Melbourne, Victoria, Australia
Wellcome HRB Clinical Research Facility
Dublin, Ireland
Health New Zealand - Te Whatu Ora - Wellington Hospital
Newtown, Wellington Region, New Zealand
University of Edinburgh
Edinburgh, United Kingdom
Leicester Clinical Research
Leicester, United Kingdom
King's College
London, United Kingdom
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.